Morgan Stanley Bullish on Immix Biopharma: Sees $1B+ Opportunity for NXC-201 CAR-T Therapy
Morgan Stanley initiated coverage on Immix Biopharma with an Overweight rating and $20 price target.
Already have an account? Sign in.